⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3335948 | 0.78 | — | — | |
| SCHEMBL3341032 | 0.78 | — | — | |
| SCHEMBL23189479 | 0.73 | — | — | |
| SCHEMBL4533845 | 0.70 | — | — | |
| SCHEMBL25315905 | 0.70 | — | — | |
| SCHEMBL25316899 | 0.70 | — | — | |
| SCHEMBL660984 | 0.69 | — | — | |
| SCHEMBL11103590 | 0.69 | — | — | |
| SCHEMBL7558516 | 0.69 | — | — | |
| Hydrochloric Acid SCHEMBL29539199 | 0.67 | L3MBTL1 (0.55) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12492199-B2 | Pyridopyrimidines as histamine H4-receptor inhibitors | FAES FARMA, S.A. (ES) | 2025-12-09 | — | — | US | disclosed |
| EP-4646425-A1 | CASPASE-2 INHIBITOR COMPOUNDS | Kintsugi Therapeutics S.L. (ES) | 2025-11-12 | — | — | EP | disclosed |
| US-20250270255-A1 | CASPASE-2 INHIBITOR COMPOUNDS | KINTSUGI THERAPEUTICS S L (ES) | 2025-08-28 | — | — | US | disclosed |
| US-20250074851-A1 | LOW TEMPERATURE SYNTHESIS OF CARBONYL-CONTAINING MOLECULES BY DEPOLYMERIZATION OF BISPHENOL A-BASED POLYCARBONATES | BASQUE CENTER FOR MACROMOLECULAR DESIGN AND ENGINEERING, POLYMAT FUNDAZIOA (ES) | 2025-03-06 | — | — | US | disclosed |
| EP-4326264-B1 | THIADIAZOLIDINONES FOR THEIR USE IN THE TREATMENT OF LIMB-GIRDLE MUSCULAR DYSTROPHY | CONSEJO SUPERIOR INVESTIGACION (ES) | 2025-01-15 | — | — | EP | disclosed |
| US-20240245657-A1 | THIADIAZOLIDINONES FOR THEIR USE IN THE TREATMENT OF LIMB-GIRDLE MUSCULAR DYSTROPHY | ADMINISTRACIÓN GENERAL DE LA COMUNIDAD AUTÓNOMA DE EUSKADI (ES) | 2024-07-25 | — | — | US | disclosed |
| WO-2024146906-A1 | CASPASE-2 INHIBITOR COMPOUNDS | Kintsugi Therapeutics S.L. (ES) | 2024-07-11 | — | — | WO | disclosed |
| EP-4397674-A1 | CASPASE-2 INHIBITOR COMPOUNDS | Kintsugi Therapeutics S.L. (ES) | 2024-07-10 | — | — | EP | disclosed |
| EP-4363436-A1 | CASPASE-2 INHIBITOR COMPOUNDS | Kintsugi Therapeutics S.L. (ES) | 2024-05-08 | — | — | EP | disclosed |
| CN-117940444-A | Caspase-2 inhibitor compounds | 金特速吉医疗有限责任公司 | 2024-04-26 | — | — | CN | disclosed |
| US-7642350-B2 | Purine derivatives | PFIZER LIMITED (GB) | 2010-01-05 | — | — | US | disclosed |
| US-20090312310-A1 | Imidazothiazole derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-12-17 | — | — | US | disclosed |
| US-20090253673-A1 | Substituted Pyrazoles as Ghrelin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2009-10-08 | — | — | US | disclosed |
| EP-2103619-A1 | IMIDAZOTHIAZOLE DERIVATIVES | Daiichi Sankyo Company, Limited (JP) | 2009-09-23 | — | — | EP | disclosed |
| EP-2043634-A2 | SUBSTITUTED PYRAZOLES AS GHRELIN RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2009-04-08 | — | — | EP | disclosed |
| EP-1888587-A1 | 2-AMIDO-6-AMINO-8-OXOPURINE DERIVATIVES AS TOLL-LIKE RECEPTOR MODULATORS FOR THE TREATMENT OF CANCER AND VIRAL INFECTIONS, SUCH AS HEPATITIS C | Pfizer Limited (GB) | 2008-02-20 | — | — | EP | disclosed |
| WO-2008008286-A2 | SUBSTITUTED PYRAZOLES AS GHRELIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2008-01-17 | — | — | WO | disclosed |
| WO-2006136917-A1 | TRIAZOLYLPIPERIDINE DERIVATIVES AND USE THEREOF IN THERAPY | PFIZER LIMITED (GB) | 2006-12-28 | — | — | WO | disclosed |
| US-20060264448-A1 | Purine derivatives | PFIZER LIMITED | 2006-11-23 | — | — | US | disclosed |
| WO-2006117670-A1 | 2-AMIDO-6-AMINO-8-OXOPURINE DERIVATIVES AS TOLL-LIKE RECEPTOR MODULATORS FOR THE TREATMENT OF CANCER AND VIRAL INFECTIONS, SUCH AS HEPATITIS C | PFIZER LIMITED (GB) | 2006-11-09 | — | — | WO | disclosed |